HS
PCVX icon

HighVista Strategies’s Vaxcyte PCVX Stock Holding History

HighVista Strategies’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.7M Buy
149,739
+25,092
+20% +$1.36M 1.98% 9
2026
Q1 		$7.24M Buy
124,647
+10,598
+9% +$575K 2% 6
2025
Q4 		$5.26M Buy
114,049
+27,247
+31% +$1.22M 1.36% 21
2025
Q3 		$3.13M Buy
86,802
+53,345
+159% +$1.77M 0.77% 38
2025
Q2 		$1.09M Buy
33,457
+355
+1% +$11.6K 0.4% 105
2025
Q1 		$1.25M Sell
33,102
-11,559
-26% -$924K 0.48% 96
2024
Q4 		$3.66M Hold
44,661
– – 1.36% 11
2024
Q3 		$5.1M Buy
44,661
+12,348
+38% +$1.11M 1.76% 3
2024
Q2 		$2.44M Buy
32,313
+22,992
+247% +$1.57M 0.89% 33
2024
Q1 		$637K Hold
9,321
– – 0.23% 109
2023
Q4 		$585K Sell
9,321
-1,927
-17% -$100K 0.21% 113
2023
Q3 		$573K Sell
11,248
-3,313
-23% -$163K 0.27% 92
2023
Q2 		$727K Sell
14,561
-5,045
-26% -$239K 0.33% 80
2023
Q1 		$735K Hold
19,606
– – 0.6% 57
2022
Q4 		$940K Sell
19,606
-1,264
-6% -$49.6K 0.56% 48
2022
Q3 		$501K Sell
20,870
-7,095
-25% -$180K 0.29% 80
2022
Q2 		$609K Buy
+27,965
New +$647K 0.37% 68

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

HighVista Strategies's PCVX Position: Q2 2026 in Review

HighVista Strategies increased its Vaxcyte (PCVX) stake by 20% in Q2 2026, buying an estimated $1.36M and bringing the position to 149,739 shares worth $8.7M. The position accounts for 1.98% of the portfolio, ranked #9.

HighVista Strategies first reported a position in PCVX in Q2 2022 and has held it in 17 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • HighVista Strategies held 149,739 shares of Vaxcyte worth $8.7M as of Q2 2026.
  • HighVista Strategies bought 25,092 Vaxcyte shares in Q2 2026, an estimated $1.36M.
  • Vaxcyte made up 1.98% of HighVista Strategies's portfolio in Q2 2026, its #9 holding.
  • HighVista Strategies first reported a position in Vaxcyte in Q2 2022 and has held it in 17 quarters since.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.